Product Code: PDB643K
“Prefillable Biological Drug Delivery Systems to 2028 ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing segment of the drug delivery sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of biological drug self-care on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.
Device Evolution and the Growth of Self-care Biologics
Specialty prefilled injection devices - a group that includes pen injectors and autoinjectors - are creating new opportunities for drug developers and marketers. These devices provide the ability to create product differentiation in the age of direct-to-consumer marketing.
Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.
What You Will Learn:
- What are the market factors driving commercial activity in the biologicals drug delivery segment?
- What are the major factors driving as-supplied product development decisions within biological drug development organizations?
- How does the availability of patient support resources influence the prescribing decision for biological drugs?
- How important are drug developer-formulation technologist relationships in the biological drug packaging segment?
- What are the key influencers regarding as-supplied packaging in the biological self-administration market segment?
- What are the significant economic, technology, and regulatory factors affecting the selection criteria for self-administered biological drugs?
Table of Contents
Executive Summary
- Prefillable Biological Drug Delivery Systems
- The Market Opportunity
- Delivery Market Dynamics
- The Economics of Injectable Drugs
- What's Driving the Growth in Injectable Devices?
- Prefilled Syringes Proliferating
- The Trend toward Self-Administration
- Shifting Demographics
- Innovation in Disposable Device Designs
Proliferation of Biological Drugs
- Therapeutic Monoclonal Antibodies
- Therapeutic Demand Drivers
- Competitive Landscape
- Risk Factors
- Prefillable Commercial Devices for Biologicals
- Manual Injection Autoinjectors
- Automated Injection Autoinjectors
- Disposable Autoinjectors
Autoinjector Product Summaries
- Molly
- Molly RNS
- Bertha
- Maggie
- Amber
- SafeLock
- VSDI +NIT
- SDI MIX +NIT
- Syrina Platform
- Syrina S
- Syrina AS
- AutoJect 2
- SelfDose
- Flexi-Q PFS
- OTS Autoinjector
- Consort Medical ASI
- Ypsomed VarioJect
- Rotaject Technology
- Viscala Autoinjector
- Flexi-Q HV
- Intevia
Wirelessly Enabled Autoinjectors
- BETACONNECT
- DataPen
- OneJet
- Alubena
- Flexi-Q eMU
- RebiSmart
- Selected Product Specific Prefillable Autoinjectors
- Alsuma/Sumatriptan Autoinjector
- Sumatriptan
- Rebif/Rebidose
- Aimovig
- Enbrel Mini AutoTouch
- Pegasys Proclick
- Rasuvo
- Otrexup
- Evzio
Device Design Factors
- Material Selection Issues
- Part Counts and Device Cost
- Safety Features
- Needle Insertion Depth
- Failsafe Activation
- Dose Inspection/Injection Confirmation
- Lyophilized Drugs/Reconstitution
- Human Engineering/Ergonomics
Pen Injectors
- Standardized Pen Platforms
- Haselmeier
- Becton Dickinson
- Owen Mumford
- Ypsomed
- SHL Medical
- Custom Pen Designs
- Reusable Pens
- Dual Chamber Pens
Commercial Pen Products
- Genotropin Pen
- Humatro-Pen/Humatro Pen 3
- Hematro-Pen Product Summary
- Norditropin
- Nutropin AQ Pen
- Nutropin AQ Pen Summary
- Omnitrope
- Omnitrope Pen Product Summary
- One.Click
- one.click Pen Product summary
- Parathyroid Hormones
- Forteo Pen
- Preotact/Preos
- Natpara
Reproductive Hormones
- Commercial Pen Products
- Follistim/Puregon Pen
- Follistim Pen Product Summary
- Gonal-f
- Gonal-f Rediject Pen Product Summary
- Wearable Devices
- Patch Pumps
- Large Volume Wearable Devices
- Wearables Product Analysis
- Libertas
- Patch Pump
- SmartDose
- Neulasta OnPro Injector
- YpsoDose
Electronic Semi-disposable
- E3D Patch Pump
- Mechanical Disposable
- enFuse
- Captive Devices
- sc2Wear Infusor
- PatchPump
- Emerging Technology
- Wireless Data
Key Therapeutic Sector Analysis
- Anaphylaxis/Countermeasures
- Autoimmune Diseases
- Rheumatoid Arthritis
- Psoriasis
- Multiple Sclerosis
- Exenatide
- Bydureon
- Pramlinitide
- Abliglutide
- Emergency Medicine
- Hepatitis
- Hematopoietics
- Hormones
- Osteoporosis
Market Factors
- Regulatory Issues
- Device Branding
- Patient Adherence and Ease of Use
- Healthcare Economics
- Company Profiles